Close Menu

NEW YORK — Sienna Cancer Diagnostics said on Friday that it has raised approximately A$1.7 million ($1.1 million) through a previously announced private stock placement. 

According to the Melbourne, Australia-based company, it sold 47.3 million shares to institutional and other certain investors at A$.0.35 per share through the private placement. Sienna also plans to offer 72 million new shares to eligible existing shareholders at the same price per share for gross proceeds of A$2.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Sponsored by

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.